JKJoseph A. Klejka

Joseph A. Klejka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Joseph A. Klejka has a total of 78 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Long-term protection following a primary series of hepatitis B vaccine in Alaska Native children and adults

    by Jonathan Steinberg, Ian Blake, Timothy Stevenson, Heather Wheelock, Dana Bruden, Lisa Townshend-Bulson, Joseph Klejka, Mark Peterson, Emily J. Cartwright, Jan Drobeniuc, et al.

    Background: Vaccination is effective at preventing chronic HBV infection and its complications, but the duration of protection and need for booster doses have not been determined. Methods: We administered a 3-dose primary series of plasma-derived hepatitis B vaccine to Alaska Native persons aged 6 months or above who resided in an HBV-endemic area of western Alaska. Persons with antibody to hepatitis B surface antigen (anti-HBs) ≥10 milli-international units per milliliter (mIU/mL) at 6 months after series completion were followed through 41 years after vaccination. Beginning at 22 years, participants with anti-HBs <10 mIU/mL were offered a booster dose (ie, challenge dose) of recombinant hepatitis B vaccine and retested 4 weeks later as a surrogate for immune memory. Combining these immune-memory data with a survival model estimating anti-HBs persistence, we estimated the overall proportion with serologic evidence of protection at 22, 30, 35, and 41 years. We also described breakthrough hepatitis B infections. Results: During 1981–1982, 1351 persons completed the hepatitis B vaccine primary series and had anti-HBs ≥10 mIU/mL at 6 months after vaccination; median age at enrollment was 13 years (range: 0.5–77). The overall proportion with serologic evidence of protection was 95% at 22 years, 95% at 30 years, 88% at 35 years, and 91% at 41 years after vaccination. At 41 years, 32% had circulating anti-HBs ≥10 mIU/mL, and 59% had immune memory. During 41 years of follow-up, 16 (1%) persons had evidence of a breakthrough infection; none developed chronic hepatitis B. Conclusions: We found serologic evidence of protection among Alaska Native persons 41 years after primary hepatitis B vaccination. Our findings support the recommendation that booster doses are not needed in endemic areas.


  • Open Access

    Impact of a Prenatal Vitamin D Supplementation Program on Vitamin D Deficiency, Rickets and Early Childhood Caries in an Alaska Native Population

    by Rosalyn J. Singleton, Gretchen M. Day, Timothy K. Thomas, Joseph A. Klejka, Christine A. Desnoyers, Melanie N. P. McIntyre, David M. Compton, Kenneth E. Thummel, Robert J. Schroth, Leanne M. Ward, et al.

    Background: Early childhood rickets increased in Alaska Native children after decreases in vitamin D-rich subsistence diet in childbearing-aged women. We evaluated the impact of routine prenatal vitamin D supplementation initiated in Alaska’s Yukon Kuskokwim Delta in Fall 2016. Methods: We queried electronic health records of prenatal women with 25(OH) vitamin D testing during the period 2015–2019. We evaluated 25(OH)D concentrations, vitamin D3 supplement refills, and decayed, missing, and filled teeth (dmft) scores and rickets in offspring. Results: Mean 25(OH)D concentrations increased 36.5% from pre- to post-supplementation; the percentage with deficient 25(OH)D decreased by 66.4%. Women with ≥ 60 vitamin D3 refill days had higher late pregnancy 25(OH)D concentrations than those with no refill days (p < 0.0001). Women with late pregnancy insufficient 25(OH)D concentrations had offspring with higher dmft scores than those with sufficient 25(OH)D (RR 1.3, p < 0.0001). Three children were diagnosed with nutritional rickets during the period 2001–2021, and none after 2017. Conclusions: These findings suggest that prenatal vitamin D supplementation can improve childhood outcomes in high-risk populations with high rates of rickets.


  • Open Access

    Life-threatening viral disease in a novel form of autosomal recessive IFNAR2 deficiency in the Arctic

    by Christopher J.A. Duncan, Morten K. Skouboe, Sophie Howarth, Anne K. Hollensen, Rui Chen, Malene L. Børresen, Benjamin J. Thompson, Jarmila Stremenova Spegarova, Catherine F. Hatton, Frederik F. Stæger, et al.

    Type I interferons (IFN-I) play a critical role in human antiviral immunity, as demonstrated by the exceptionally rare deleterious variants of IFNAR1 or IFNAR2. We investigated five children from Greenland, Canada, and Alaska presenting with viral diseases, including life-threatening COVID-19 or influenza, in addition to meningoencephalitis and/or hemophagocytic lymphohistiocytosis following live-attenuated viral vaccination. The affected individuals bore the same homozygous IFNAR2 c.157T>C, p.Ser53Pro missense variant. Although absent from reference databases, p.Ser53Pro occurred with a minor allele frequency of 0.034 in their Inuit ancestry. The serine to proline substitution prevented cell surface expression of IFNAR2 protein, small amounts of which persisted intracellularly in an aberrantly glycosylated state. Cells exclusively expressing the p.Ser53Pro variant lacked responses to recombinant IFN-I and displayed heightened vulnerability to multiple viruses in vitro—a phenotype rescued by wild-type IFNAR2 complementation. This novel form of autosomal recessive IFNAR2 deficiency reinforces the essential role of IFN-I in viral immunity. Further studies are warranted to assess the need for population screening.


  • Open Access

    Healthy Pregnancies Project: Cluster Randomized Controlled Trial of a Community Intervention to Reduce Tobacco Use among Alaska Native Women

    by Christi A. Patten, Harry A. Lando, Chris A. Desnoyers, Martha J. Bock, Lucinda Alexie, Paul A. Decker, Christine A. Hughes, Kenneth Resnicow, Linda Burhansstipanov, Rahnia Boyer, et al.

    Substantial gaps remain in the evidence base for prenatal tobacco use interventions among Indigenous women. Using a cluster randomized controlled trial (RCT), the Healthy Pregnancies Project evaluated a community-level intervention for Alaska Native (AN) women in rural western Alaska. Sixteen villages were randomly assigned to usual care (control, n = 8 villages) or usual care plus a community-level intervention delivered by local AN “Native Sisters” (n = 8 villages). Outcomes were tobacco use rate at delivery and at 2 and 6 months postpartum, with biochemical confirmation obtained at 6 months. The program had high reach, enrolling 73% of all eligible women screened. Of the 352 participants, 67% used tobacco at baseline. No significant differences emerged between study groups on follow-up in tobacco use rates. More intervention than control participants made a quit attempt at 2 months postpartum (70% vs. 51%, respectively, p = 0.012). Participants in both study groups reported the program helped to raise awareness of healthy pregnancies in the study villages. This trial supports the reach of a community-level intervention, but not its efficacy for reducing tobacco use during pregnancy or postpartum. Efforts to sustain early quit attempts appear warranted. The community involvement, and reported impact on raising awareness of the importance of healthy pregnancies, supports the value of the research program in this community.


  • Open Access

    The Healthy Pregnancies Project: Study protocol and baseline characteristics for a cluster-randomized controlled trial of a community intervention to reduce tobacco use among Alaska Native pregnant women

    by Christi A. Patten, Harry A. Lando, Chris A. Desnoyers, Yvette Barrows, Joseph Klejka, Paul A. Decker, Christine A. Hughes, Martha J. Bock, Rahnia Boyer, Kenneth Resnicow, et al.


  • Open Access

    A survey of knowledge, attitudes, and practices towards skin and soft tissue infections in rural Alaska

    by Gregory A. Raczniak, Joanna Gaines, Lisa R. Bulkow, Michael H. Kinzer, Thomas W. Hennessy, Joseph A. Klejka, Michael G. Bruce

    A survey of knowledge, attitudes, and practices towards skin and soft tissue infections in rural Alaska